Long-term effectiveness of COVID-19 vaccination in preventing hospitalization among household contacts: A case–control study from December 2021 to April 2023

We aimed to assess the long-term effect of Coronavirus disease 2019 (COVID-19) vaccination in improving infection, symptoms and disease severity more than 1 year. Consecutive adult inpatients diagnosed with COVID-19 through clinical criteria from two hospitals with household contacts were included. The exposure was COVID-19 vaccination. The primary outcome was hospitalization, while infection, symptoms, and pneumonia were assessed as exploratory outcomes. Multivariable logistic regression, subgroup and sensitivity analysis were conducted. From December 18, 2022, to April 7, 2023, 1,410 individuals were prospectively screened, and 1,047 individuals were included. The male proportion was 49.24% with the mean age of 66.10 years. A total of 883 (84.34%) participants were vaccinated with a median time of 297.5 (157.0, 389.0) days between the last vaccine and enrollment, and a median time of 446.5 (162.8, 504.8) days was found in fully vaccinated patients. The infection rate among unvaccinated patients was significantly higher (96.72% vs. 88.69%, <i>p</i> < .001). Unvaccinated patients reported less symptoms, including sore throat, myalgia and taste disorder. They had a higher hospitalization rate (80.49% vs. 45.07%). In multivariable logistic regression, vaccination was associated with reduced pneumonia risk (aOR: 0.49, 95% CI: 0.32-0.76, <i>p</i> = .002). In addition, significant negative association between vaccination and hospitalization risk (aOR: 0.37, 95% CI: 0.26-0.61, <i>p</i> < .001) was observed. For vaccination status, the booster vaccination group revealed the aOR of 0.40 (95% CI: 0.24-0.65, <i>p</i> < .001), while the fully vaccination group only presented with the aOR of 0.50 (95% CI: 0.28-0.87, <i>p</i> = .013). While COVID-19 vaccination may not provide protection against symptoms beyond 1 year, it maintains durable effectiveness in reducing the risk of hospitalization.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2025-10-28
DOI
https://doi.org/10.1080/21645515.2025.2563760
Primary Topic
Vaccine Coverage and Hesitancy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term effectiveness of COVID-19 vaccination in preventing hospitalization among household contacts: A case–control study from December 2021 to April 2023

Yi Mu, Xiaoyu Cao, Mingfeng Han, Hui Zhang et al.
Human Vaccines & Immunotherapeutics
Vaccine Coverage and Hesitancy
article

Long-term effectiveness of COVID-19 vaccination in preventing hospitalization among household contacts: A case–control study from December 2021 to April 2023

Yi Mu, Xiaoyu Cao, Mingfeng Han, Hui Zhang, Shasha Li, Limin Zhang, Yeming Wang, Dong Liu, Ruirui Wang, Bin Cao
article en

Abstract

We aimed to assess the long-term effect of Coronavirus disease 2019 (COVID-19) vaccination in improving infection, symptoms and disease severity more than 1 year. Consecutive adult inpatients diagnosed with COVID-19 through clinical criteria from two hospitals with household contacts were included. The exposure was COVID-19 vaccination. The primary outcome was hospitalization, while infection, symptoms, and pneumonia were assessed as exploratory outcomes. Multivariable logistic regression, subgroup and sensitivity analysis were conducted. From December 18, 2022, to April 7, 2023, 1,410 individuals were prospectively screened, and 1,047 individuals were included. The male proportion was 49.24% with the mean age of 66.10 years. A total of 883 (84.34%) participants were vaccinated with a median time of 297.5 (157.0, 389.0) days between the last vaccine and enrollment, and a median time of 446.5 (162.8, 504.8) days was found in fully vaccinated patients. The infection rate among unvaccinated patients was significantly higher (96.72% vs. 88.69%, <i>p</i> < .001). Unvaccinated patients reported less symptoms, including sore throat, myalgia and taste disorder. They had a higher hospitalization rate (80.49% vs. 45.07%). In multivariable logistic regression, vaccination was associated with reduced pneumonia risk (aOR: 0.49, 95% CI: 0.32-0.76, <i>p</i> = .002). In addition, significant negative association between vaccination and hospitalization risk (aOR: 0.37, 95% CI: 0.26-0.61, <i>p</i> < .001) was observed. For vaccination status, the booster vaccination group revealed the aOR of 0.40 (95% CI: 0.24-0.65, <i>p</i> < .001), while the fully vaccination group only presented with the aOR of 0.50 (95% CI: 0.28-0.87, <i>p</i> = .013). While COVID-19 vaccination may not provide protection against symptoms beyond 1 year, it maintains durable effectiveness in reducing the risk of hospitalization.

Human Vaccines & ImmunotherapeuticsVol. 21(1)
Academy of Medical Sciences (GB), Fuyang Normal University (CN), Cornerstone University (US), Capital University (US), Harbin Medical University (CN), Capital Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), China-Japan Friendship Hospital (CN), Peking Union Medical College Hospital (CN), National Clinical Research Center for Digestive Diseases (CN), National Clinical Research (US), Second Affiliated Hospital of Harbin Medical University (CN), Corner House (GB), Pulmonary and Critical Care Associates (US), Fuyang Second People's Hospital (CN)
Openalex Percentile: Top 61%
Vaccine Coverage and Hesitancy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.